Immunology and inflammation

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer's spesolimab data raises hope for serious skin di...

Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim's spesolimab has shown encouraging efficacy in a phase 2 trial in generalised pustular psoriasis (GPP), a rar

News

FDA knocks back Takeda's blockbuster hope TAK-721

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first appro

News

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking

News

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage ulcerative colitis drug etras

News

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start

News

Strike two for Novartis' lung cancer antibody canakinumab

Expectations for Novartis' canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objecti

Boehringer's spesolimab data raises hope for serious skin di...

FDA knocks back Takeda's blockbuster hope TAK-721

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

Strike two for Novartis' lung cancer antibody canakinumab

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

Immunology and inflammation

Editor's Picks